- Jasper Therapeutics ( NASDAQ: JSPR ) on Wednesday said a European drug regulator committee had granted an orphan drug designation to its monoclonal antibody as a conditioning treatment for patients before they get a stem cell transplant.
- The designation was granted by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products to JSPR's briquilimab, a monoclonal antibody targeting the stem cell factor receptor.
- The EMA's orphan designation is given to medicines developed for rare, life-threatening diseases.
- “The EMA's decision to grant orphan drug designation to briquilimab highlights the clear need for non-genotoxic, targeted conditioning for patients receiving hematopoietic stem cell transplant," JSPR CEO Ronald Martell said in a statement .
- The orphan drug designation announcement comes a day after shares of Jasper ( JSPR ) rocketed higher by more than 400% on positive data from an early-to-mid stage trial for blood disorders.
- JSPR stock was down 12% to $2.41 after the opening bell.
For further details see:
Jasper gets European orphan drug designation for pre-transplant conditioning treatment